Paroxysmal Nocturnal Hemoglobinuria Treatment Market: By Treatment Type (Stem Cell Transplant and Blood Transfusion), By Drug Type (Anti C5 Monoclonal Antibodies, Danicopan, Iron supplements, and Others), By Distribution Channel (Retail, Hospital Pharmacies, Online Pharmacy), and Geography

Paroxysmal Nocturnal Hemoglobinuria Treatment Market was valued at USD 6.4 billion in 2022 and is projected to reach USD 12.3 Billion by 2029, growing at a 6.2% CAGR from 2023 to 2029. Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder that leads to the premature death and impaired production of blood cells, it presents clinically with a variety of symptoms, the most prevalent of which are hemolytic anemia, hemoglobinuria, and somatic symptoms including fatigue and shortness of breath, increase in the prevalence of blood disorder globally consequences rise in PNH treatment market growth, According to National Organization of Rare Diseases, The prevalence is estimated to be between 0.5-1.5 per million people in the general population, affects males and females in equal numbers, although some studies show a slightly more female affected.

The industry is influenced by continuous technological development in healthcare infrastructure along with research and development to improve specific therapies which leads to the major factor that drives the market growth. With the rising prevalence of hemoglobinuria globally the key players focusing on research and development activities and undergoing clinical trials for the treatment, in addition, the numerous approaches for the development of anti-C5 monoclonal antibodies influence the revenue growth leads to create lucrative opportunities in the Paroxysmal Nocturnal Hemoglobinuria Treatment market. To treat patients with repeated hemolysis and anemia, blood transfusion, and iron supplements were administered to cause adverse reactions, also the unavailability of specialty professionals limits the market growth, high cost of treatment hampers the emerging economics countries’ market resist the growth of Paroxysmal Nocturnal Hemoglobinuria Treatment market.